"...the agency enters 2013 with the additional power of the Food and Drug Administration Safety and Innovation Act, passed this summer. The law confers a “breakthrough therapy” label to drugs that may treat a serious or life-threatening condition based on preliminary clinical evidence. 

The agency granted two Breakthrough Therapy labels for 2012 as of December 10, and denied one. The agency's December 10 report also noted that it closed the year with an all-time high of New Molecular Entity first-cycle approval rates.
What's most important is that from the patient's standpoint, 2012 was a good year. A lot of good new drugs were approved,” Pines said. (Más)